At data cut-off (02 October 2015), two patients, one with RCC receiving 15 mg QW (dose escalation; 58 cycles) and one with TORC1 inhibitor−naïve RCC receiving 30 mg QW (expansion; 26 cycles), were still receiving study drug. Here, CRTC1 is linked to renal cell adenocarcinoma.